The future of the US Dry Age-Related Macular Degeneration AMD Market will be defined by continued innovation, personalized medicine, and expanding applications across telemedicine, AI-driven diagnostics, and genetic profiling. The market is projected to grow at an 8.3% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing patient awareness. This growth trajectory reflects the fundamental role of dry AMD treatments in preserving vision and improving quality of life for a growing demographic of elderly patients.
A major emerging trend is the diversification of therapeutic approaches beyond complement inhibition. In 2025, complement inhibitors captured 31% of the dry AMD treatment segment, followed by nutritional supplements at 24%, neuroprotective therapies at 11%, low-vision rehabilitation devices at 10%, cell-based therapies at 9%, gene therapy at 8%, and supportive care at 7%. The strategic picture is becoming clearer: the 31% complement-inhibitor share represents today's commercial reality, while the 9% cell-based therapy and 8% gene therapy shares represent tomorrow's technology direction.
The market is witnessing increased focus on early diagnosis and preventive care through OCT imaging, AI-based retinal screening, and tele-ophthalmology. The next competitive advantage may not simply be "which drug slows progression?" It could be: Which therapy lasts longer? Which treatment requires fewer injections? Which technology detects progression earlier? And which platform can preserve or restore vision rather than only slow retinal damage? Investment in personalized treatment plans based on genetic profiling is gaining traction, enabling healthcare providers to tailor treatments to individual patient profiles.
Key unmet needs persist, including limited durable treatment options, high injection burden, under-treatment in early disease, and uneven access to specialized care. As a result, companies developing long-acting biologics, gene therapies, and disease-modifying treatments are expected to gain a strong competitive advantage. By 2035, the US dry AMD market will be more intelligent, personalized, and patient-centric than ever before, reflecting evolving healthcare needs and technological innovations in ophthalmology. Do you think personalized treatment plans will eventually become the standard of care for dry AMD in the US?
FAQs
What is driving growth in the US dry AMD market?
Key drivers include the rising aging population, increasing prevalence of AMD, rising healthcare expenditure, government initiatives and funding, and advancements in diagnostic technologies.
How are emerging therapies shaping the market?
Oral therapies, gene therapies, and cell-based therapies offer alternatives to chronic intravitreal injections and potential disease-modifying benefits, diversifying the treatment landscape.
#USDryAMDMarket #FutureOutlook #PersonalizedMedicine #GeneTherapy #OphthalmologyInnovation
